ライフサイエンスコーパス: hematologic disorder

1 n with and without ovarian cancer (none with hematologic disorder).

2 hest used to date to investigate a malignant hematologic disorder.

3 Polycythemia vera (PV) is a human clonal hematologic disorder.

4 od of some persons who are not known to have hematologic disorders.

5 c stem and progenitor cells and treatment of hematologic disorders.

6 more frequently in the treatment of various hematologic disorders.

7 n myelodysplastic syndromes (MDSs) and other hematologic disorders.

8 underpinnings of nonmalignant and malignant hematologic disorders.

9 g as new therapeutics for cardiovascular and hematologic disorders.

10 stem cell gene transfer for the treatment of hematologic disorders.

11 etic stem cells transplantation for treating hematologic disorders.

12 ble diagnostic and prognostic information in hematologic disorders.

13 -saving treatment modality for patients with hematologic disorders.

14 eserve and renewal capacity in patients with hematologic disorders.

15 treatment of patients with life-threatening hematologic disorders.

16 isense approach targeting Bcl-2 in malignant hematologic disorders.

17 keletal muscle of animal models of inherited hematologic disorders.

18 lar bases of numerous acquired and inherited hematologic disorders.

19 lts in cardiovascular, renal, placental, and hematologic disorders.

20 sible for patients with a growing variety of hematologic disorders.

21 ll proliferation that may be associated with hematologic disorders.

22 rapy holds promise for the treatment of many hematologic disorders.

23 er studies of HITT and other immune-mediated hematologic disorders.

24 is disease to transform into more aggressive hematologic disorders.

25 0); systemic mastocytosis with an associated hematologic disorder, 1320 (n = 7); aggressive mastocyto

26 ommon causes included vasculitis (34.6%) and hematologic disorders (27.4%).

27 OG) performance status 2; 51% for antecedent hematologic disorder; 54% for intermediate karyotype; 42

28 e thrombocytopenic purpura (ITP) is a common hematologic disorder; about 14,000 to 16,000 new cases o

29 Hematologic disorders account for a large proportion of

30 peutic option for patients with nonmalignant hematologic disorders and can mediate immune tolerance t

31 ophil number and survival are common to both hematologic disorders and chronic inflammatory diseases.

32 with high rates of success for a variety of hematologic disorders and metabolic storage diseases in

33 44) compared with the sera of patients with hematologic disorders and no histologic evidence of fibr

34 erse effects and benefits of splenectomy for hematologic disorders and other conditions demand furthe

35 ormance status, or presence of an antecedent hematologic disorder, and multivariate analysis indicate

36 t, treatment recommendations for less common hematologic disorders are consistent with current standa

37 The hematologic disorders are described, and a correlation w

38 agnosing, treating, and palliating malignant hematologic disorders are inadequate.

39 ), but not blood cells from normals or other hematologic disorders, are resistant to the cytotoxic ef

40 file of Mood States (POMS) for patients with hematologic disorders as compared with patients with bre

41 , local or systemic infections, vascular and hematologic disorders, autoimmune diseases, and environm

42 e to rule out BM involvement in a variety of hematologic disorders before or after therapy.

43 of gene therapy strategies for treatment of hematologic disorders by AdVec.

44 Sickle cell disease (SCD) is a hematologic disorder caused by a missense mutation in th

45 opathic hypereosinophilic syndrome is a rare hematologic disorder characterized by sustained unexplai

46 oplasms (MPNs) are a group of related clonal hematologic disorders characterized by excess accumulati

47 romes (MDS) comprise a group of premalignant hematologic disorders characterized by ineffective hemat

48 consequence, many human leukemias and other hematologic disorders do not robustly engraft in these c

49 wide spectrum of nonmalignant and malignant hematologic disorders, genetic disorders, and solid tumo

50 us-host disease, viral infections, malignant hematologic disorders, hemophilia, and the hemoglobin di

51 l types of malignant hematologic disease and hematologic disorders; however, these patients have an i

52 The hematologic disorder in these patients is more consisten

53 NS is also associated with a spectrum of hematologic disorders, including juvenile myelomonocytic

54 enesis has been demonstrated in a variety of hematologic disorders, including multiple myeloma.

55 sequencing that have been applied to benign hematologic disorders, including those affecting the red

56 granulomatous disease (CGD) is an inherited hematologic disorder involving failure of phagocytic cel

57 purpura (ITP) is the most common autoimmune hematologic disorder, little is known about the associat

58 c thrombocytopenic purpura (ITP) is a common hematologic disorder manifested by immune-mediated throm

59 emonstrates high prevalence in patients with hematologic disorders, most commonly sickle cell disease

60 No new hematologic disorders occurred.

61 Neoplastic hematologic disorders of the myeloid lineage have been r

62 netic subgroup, age, and history of previous hematologic disorder or antineoplastic therapy.

63 years); 22 patients (59%) had an antecedent hematologic disorder or myelodysplastic syndrome or both

64 tients), leukemia arising from an antecedent hematologic disorder or prior cytotoxic therapy (seconda

65 Nineteen (36%) had antecedent hematologic disorder or therapy-related AML; 16 had comp

66 , but not in marrow from patients with other hematologic disorders or controls, and support an import

67 years), we estimated the cumulative risk of hematologic disorders originating from lymphoid and myel

68 rable cytogenetics (P < .001) and antecedent hematologic disorder (P < .001), and had a higher presen

69 ere negatively correlated with an antecedent hematologic disorder (P = .002) but not with age or cyto

70 Sixty-eight adults with life-threatening hematologic disorders received intensive chemotherapy or

71 for the pathogenesis of these poor prognosis hematologic disorders remain controversial.

72 Hematologic disorders such as aplastic anemia and leukem

73 The pathogenesis of hematologic disorders such as aplastic anemia and the de

74 clinical and preclinical settings, including hematologic disorders such as the hemophilias, Gaucher d

75 For the psychologic data, patients with hematologic disorders tended to be more distressed than

76 e myelodysplastic syndrome (MDS) is a clonal hematologic disorder that frequently evolves to acute my

77 Myelodysplastic syndromes (MDS) are common hematologic disorders that are characterized by decrease

78 Myelodysplastic syndromes (MDSs) are clonal hematologic disorders that frequently represent an inter

79 The myelodysplastic syndromes are a group of hematologic disorders that often evolve into secondary a

80 ditioning is a cure for several nonmalignant hematologic disorders that require chronic transfusion,

81 alpha might be involved in several malignant hematologic disorders, the mutational status of this reg

82 a curative therapy for several nonmalignant hematologic disorders through the provision of donor-der

83 greater than 50 IU/L (P = .02), diagnosis of hematologic disorder versus solid tumor (P = .06), serum

84 An underlying hematologic disorder was detected in 69 patients (78%).

85 A search for hematologic disorders was negative.

86 Hematologic disorders were associated with the highest h

87 tients with ongoing renal failure or chronic hematologic disorders were excluded.

88 ologic measures when comparing patients with hematologic disorders with those with breast cancer.